Continuous Glucose Monitoring Patent Landscape 2026
Continuous Glucose Monitoring Patent Landscape in 2026
The continuous glucose monitoring (CGM) patent field is heavily concentrated, with Dexcom and Abbott Diabetes Care together commanding the largest share among the top filers, and diagnostic sensor design (A61B) anchoring the dominant technology route. The field peaked in 2021 and annual volume has since eased, though the multi-year body of prior art remains substantial at 10,707 patent families.
Dexcom leads a highly concentrated field with a clear top-tier gap
Dexcom Inc holds the top position among all applicants, followed by Abbott Diabetes Care Inc in second and Medtronic MiniMed Inc in third. These three players, along with I-Sens Inc and F. Hoffmann-La Roche, constitute the top five, collectively accounting for 57% of the combined patent records held by the hundred largest filers.
The gap between the first-tier players and the rest of the field is pronounced. Dexcom’s record count is roughly 35% larger than Abbott’s, and both sit far above Medtronic MiniMed in third. Below the top three, rankings four through ten are more closely bunched, suggesting a competitive but lower-volume second tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 4,196 | |
| 2 | Abbott Diabetes Care Inc | 3,093 | |
| 3 | Medtronic MiniMed Inc | 1,660 | |
| 4 | I-Sens Inc | 1,082 | |
| 5 | F HOFFMANN LA ROCHE & CO AG | 1,041 | |
| 6 | Roche Diabetes Care GmbH | 528 | |
| 7 | Medtrum Technologies Inc | 526 | |
| 8 | Roche Diabetes Care Inc | 484 | |
| 9 | Ascensia Diabetes Care Holdings AG | 460 | |
| 10 | Senseonics Inc | 374 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | University of Virginia Patent Foundation | 341 | |
| 12 | Insulet Corporation | 311 | |
| 13 | Bionime Corporation | 275 | |
| 14 | The Regents of the University of California | 240 | |
| 15 | BECTON DICKINSON & CO | 235 | |
| 16 | Bigfoot Biomedical Inc | 176 | |
| 17 | Biolinq Inc | 151 | |
| 18 | Roche Diagnostics GmbH | 144 | |
| 19 | LifeScan Inc | 134 | |
| 20 | Novo Nordisk A/S | 123 |
Dexcom and Abbott’s dominant positions reflect deep, long-standing investment in core sensor, algorithm, and connectivity IP. Entrants seeking differentiation will find the canonical diagnostic sensor space heavily defended, making adjacent technology routes — informatics, drug-delivery integration, wireless — relatively more accessible.
The most recent 18–24 months of filing data are affected by publication lag and will undercount actual activity; trend reads for 2024–2026 should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing volume peaked in 2021; sensor diagnostics dominate the technology mix
Annual filing data and technology branch composition together show a maturing field with a concentrated core and a dispersed set of adjacent branches — a structure that shapes where new entrants can realistically compete.
Annual filing trend
Filings grew steadily from 2017 through 2021, reaching a peak before easing in subsequent years. The reductions visible in 2022–2024 reflect a genuine post-peak slowdown, while 2025–2026 figures are additionally suppressed by publication lag and should not be read as a continuation of decline. The field is still active on a multi-year basis but annual origination has moderated from its 2021 high.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis and surgery) is the overwhelmingly dominant IPC class, consistent with the field’s foundation in implantable and wearable sensor hardware. G01N (Material analysis and testing) and G16H (Healthcare informatics) are significant secondary branches, reflecting electrochemical sensor chemistry and data management. Wireless communication branches (H04W, H04L) and AI/computing branches (G06N) are present but relatively sparse, signaling where new technical investment remains thinner.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Subcutaneous glucose electrode | 2,642 |
| 2 | Closed loop infusion pump system with removable gl… | 2,294 |
| 3 | Subcutaneous glucose electrode | 2,239 |
| 4 | Integrated delivery device for continuous glucose … | 2,228 |
| 5 | Diabetes management system | 2,084 |
| 6 | Systems and methods for replacing signal artifacts… | 1,997 |
| 7 | Electrochemical sensor and integrity tests therefor | 1,961 |
| 8 | Implantable glucose sensor | 1,922 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What field structure and lifecycle mean for R&D investment decisions
Four structural dimensions — maturity, concentration, collaboration, and geography — each carry direct implications for where new R&D investment can find defensible space.
Post-peak maturation: core sensor IP is well-established
The lifecycle stage is assessed as Decline, with annual filings easing back from the 2021 peak. This reflects a maturing core — foundational subcutaneous sensor and closed-loop pump integration concepts are densely patented. New entrants should focus on differentiated sub-technologies rather than core sensor mechanics, which are heavily prior-arted.
Lifecycle: DeclineTop-five filers hold 57% of the largest-filer pool
The top five applicants account for 57% of the combined patent records among the hundred largest filers, indicating a strongly oligopolistic structure. The tier gap between Dexcom and the challengers is wide. Competing head-to-head on core diagnostic sensor IP against Dexcom or Abbott requires exceptional resource depth; adjacent branches offer more tractable entry points.
High concentrationRoche entities are the most active co-filers; academic partnerships also evident
The most active co-applicant relationships are within the Roche group: F. Hoffmann-La Roche co-files most frequently with Roche Diabetes Care Holdings (254 joint records), Roche Diagnostics Operations (190), and Roche Diabetes Care GmbH (78). Outside the Roche ecosystem, I-Sens co-files with Sogang University Research and Business Development Foundation (27 records), Abbott Diabetes Care co-files with the University of Virginia Patent Foundation (22 records) and Cambridge Enterprise (12 records), and F. Hoffmann-La Roche has 9 joint records with IBM.
Ecosystem co-filingUS-centric filing; Europe and PCT are meaningful secondary jurisdictions
The United States is the dominant filing jurisdiction by a wide margin, followed by Europe (EPO) and WIPO (PCT) as the primary international routes. Canada and Australia rank as secondary anglophone markets. China, Japan, South Korea, and India show notably lower coverage relative to their CGM market scale, which may represent a strategic gap for applicants seeking broader geographic protection.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| F. Hoffmann-La Roche Ltd | Roche Diabetes Care Holdings AG | 254 |
| F. Hoffmann-La Roche Ltd | Roche Diagnostics Operations Inc | 190 |
| F. Hoffmann-La Roche Ltd | Roche Diabetes Care GmbH | 78 |
| Roche Diabetes Care Holdings AG | Roche Diabetes Care GmbH | 73 |
| I-Sens Inc | SOGANG UNIV RES & BUSINESS DEV FOUND | 27 |
| Abbott Diabetes Care Inc | University of Virginia Patent Foundation | 22 |
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 12 |
| F. Hoffmann-La Roche Ltd | IBM (International Business Machines Corporation) | 9 |
| F. Hoffmann-La Roche Ltd | Roche Diagnostics Operations Inc | 8 |
| Roche Diabetes Care Holdings AG | IBM (International Business Machines Corporation) | 6 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom anchors diagnostics and informatics; Abbott shows positive recent momentum
The two dominant players diverge in recent trajectory: Dexcom’s filing volume has pulled back while Abbott has grown, narrowing the gap at the top of the ranking.
Dexcom Inc
Dexcom holds the largest patent record count among all applicants. Its technology emphasis is concentrated in A61B 5 (diagnostic sensor systems), with secondary coverage in G16H 40 and G16H 20 (healthcare informatics and clinical decision support). Recent filing momentum is down 24% versus the prior period, suggesting the company is consolidating rather than accelerating its IP estate.
patent records: 4,196Abbott Diabetes Care Inc
Abbott Diabetes Care ranks second with 3,093 patent records. Its technology focus mirrors Dexcom’s core A61B 5 emphasis but extends more strongly into G01N 33 (electrochemical material analysis), reflecting its sensor chemistry heritage. Abbott is the only top-tier player showing positive recent momentum at +10%, suggesting active new IP generation that may be narrowing Dexcom’s lead over time.
patent records: 3,093| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 639 | ▼ -24% |
| Abbott Diabetes Care Inc | 480 | ▲ +10% |
| Medtronic MiniMed Inc | 170 | ▼ -43% |
| I-Sens Inc | 189 | ▼ -59% |
| F. Hoffmann-La Roche Ltd | 85 | ▼ -33% |
| Senseonics Inc | 51 | ▼ -41% |
| Roche Diabetes Care Holdings AG | 58 | ▼ -12% |
| Roche Diabetes Care GmbH | 81 | ▬ -2% |
Under-served adjacent branches worth watching in CGM IP strategy
Several IPC branches adjacent to the dominant A61B core show meaningful patent volume but lower relative share, indicating areas where the competitive density is lower and where technical differentiation may be more achievable.
H04W · Wireless communication networks
Wireless communication (H04W) accounts for a relatively small share of the IPC mix despite being a functional prerequisite for modern CGM systems — real-time glucose data transmission to smartphones, insulin pumps, and cloud platforms all depend on it. The sparse coverage relative to sensor hardware suggests that applicants specializing in low-power, secure, or high-reliability wireless protocols for implantable medical devices could build a defensible position without directly confronting the dominant sensor IP holders. A realistic entry path runs through protocol-level or antenna-design innovation specific to body-worn medical devices.
Search this in Eureka →G06N · Computing based on AI models
AI and machine-learning models (G06N) appear in only a small fraction of the total IPC record set despite growing clinical interest in predictive glucose algorithms, personalized dosing recommendations, and hypoglycemia early-warning systems. The branch is technically adjacent to the G16H informatics coverage held by leaders like Dexcom and Abbott, but model-level innovation — particularly in edge inference on wearable hardware or federated learning across CGM fleets — remains comparatively sparse. Applicants with ML platform expertise and access to continuous glucose datasets could establish IP in this sub-space without replicating existing sensor hardware claims.
Search this in Eureka →How leaders differ by technology route across CGM sub-domains
Strength of each leader across the main technology routes.
| Player | A61B 5 · Diagnosis & surgery | G01N 33 · Material analysis & testing | G01N 27 · Material analysis & testing | A61M 5 · Devices for body fluids | G16H 40 · Healthcare informatics |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 3,607 | Emerging · 411 | Emerging · 407 | Emerging · 368 | Emerging · 711 |
| Abbott Diabetes Care Inc | Strong · 2,544 | Emerging · 354 | Emerging · 245 | Emerging · 317 | Emerging · 404 |
| Medtronic MiniMed Inc | Strong · 1,292 | Emerging · 205 | Moderate · 328 | Moderate · 412 | Emerging · 171 |
| F. Hoffmann-La Roche Ltd | Strong · 604 | Moderate · 134 | Moderate · 171 | Emerging · 72 | Emerging · 87 |
| I-Sens Inc | Strong · 797 | Absent | Absent | Absent | Absent |
| University of Virginia Patent Foundation | Strong · 263 | Absent | Absent | Moderate · 130 | Moderate · 108 |
| Senseonics Inc | Strong · 282 | Moderate · 71 | Absent | Absent | Absent |
Frequently asked questions
Dexcom Inc leads with 4,196 patent records among the top-ranked applicants, followed by Abbott Diabetes Care Inc with 3,093 and Medtronic MiniMed Inc with 1,660. These three form a clear top tier, well ahead of the remaining ranked filers.
Annual filing volume peaked in 2021 and has eased since then — the lifecycle stage is assessed as Decline based on a multi-year growth rate of -21%. The most recent years (2024–2026) are also affected by publication lag, so those figures undercount actual activity. The multi-year patent estate remains large at 10,707 patent families.
The United States is the dominant filing jurisdiction by a wide margin, followed by Europe (EPO) and WIPO (PCT) as the primary international routes, then Canada and Australia as secondary markets. China, Japan, and South Korea show comparatively limited coverage despite their CGM market scale.
The most-cited works include patents titled ‘Subcutaneous glucose electrode,’ ‘Closed loop infusion pump system with removable glucose sensor,’ ‘Integrated delivery device for continuous glucose monitoring,’ ‘Diabetes management system,’ ‘Systems and methods for replacing signal artifacts,’ ‘Electrochemical sensor and integrity tests therefor,’ and ‘Implantable glucose sensor.’ These represent the foundational IP layer that subsequent filings build upon or design around.
Wireless communication networks (H04W) and AI/machine-learning computing (G06N) both show lower relative share in the IPC mix despite being functionally important to modern CGM systems. These branches represent areas where new entrants may find more tractable IP positions without competing directly on core sensor hardware claims.
The most active co-filing relationships are within the Roche corporate group, with F. Hoffmann-La Roche co-filing most frequently with Roche Diabetes Care Holdings (254 joint records), Roche Diagnostics Operations (190), and Roche Diabetes Care GmbH (78). Academic partnerships are also evident: I-Sens co-files with Sogang University Research and Business Development Foundation (27 records), and Abbott Diabetes Care co-files with the University of Virginia Patent Foundation (22 records) and Cambridge Enterprise (12 records).
Ready to map your own CGM patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.